Drug Trial Radar · NCT05270668
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
154
Actual
Start
Mar 29, 2022
Primary completion
Apr 16, 2026
Study completion Nov 16, 2026
Sponsor
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interstitial Lung Disease
Interventions
TulisokibartDrug
Tulisokibart administered at timepoints as directed by the protocol
Companion diagnostic ( CDx)Diagnostic test
CDx+ or CDx-
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experience an Adverse Event (AE)Time frame: Up to Week 50
- Number of Participants who Experience a Serious Adverse Event (SAE)Time frame: Up to Week 50
- Number of Participants who Discontinue due to an AETime frame: Up to Week 50
- Change from Baseline in the Annual Rate of Change in Forced Vital Capacity (FVC) at Week 50Time frame: Baseline and up to Week 50
Locations
95 sites in 20 countries. Site status is shown where the registry gives one.
Mayo Clinic - Scottsdale ( Site 4014)
Phoenix, Arizona
Pacific Arthritis Care Center ( Site 4008)
Los Angeles, California
Cedars Sinai Medical Center ( Site 4010)
Los Angeles, California
UCLA School of Medicine ( Site 4006)
Los Angeles, California
Stanford Health Care ( Site 4009)
Palo Alto, California
National Jewish Health Medical Center ( Site 4015)
Denver, Colorado
Yale University ( Site 4017)
New Haven, Connecticut
MedStar Georgetown University Hospital ( Site 4005)
Washington D.C., District of Columbia
Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018)
Baltimore, Maryland
Massachusetts General Hospital ( Site 4003)
Boston, Massachusetts
Boston University School of Medicine ( Site 4021)
Boston, Massachusetts
University of Michigan Hospital ( Site 4001)
Ann Arbor, Michigan
Rutgers Robert Wood Johnson Medical School ( Site 4013)
New Brunswick, New Jersey
Hospital For Special Surgery ( Site 4020)
New York, New York
Cleveland Clinic Foundation ( Site 4019)
Cleveland, Ohio
University of Toledo Medical Center ( Site 4002)
Toledo, Ohio
University of Pittsburgh Medical Center ( Site 4016)
Pittsburgh, Pennsylvania
Medical University of South Carolina - PPDS ( Site 4004)
Charleston, South Carolina
UT Physicians Rheumatology ( Site 4007)
Houston, Texas
Froedtert and Medical College of Wisconsin ( Site 4012)
Milwaukee, Wisconsin
Consultorios Médicos Dr. Doreski ( Site 4800)
CABA, Buenos Aires, Argentina
Clínica Privada Independencia ( Site 4802)
Munro, Buenos Aires, Argentina
Centro de Investigación Instituto Médico Río Cuarto ( Site 4801)
Río Cuarto, Córdoba Province, Argentina
Instituto Medico de la Fundacion Estudios Clinicos ( Site 4803)
Rosario, Santa Fe Province, Argentina
Royal Adelaide Hospital ( Site 4050)
Adelaide, South Australia, Australia
St Vincents Hospital Melbourne ( Site 4051)
Melbourne, Victoria, Australia
UZ Gent ( Site 4401)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 4402)
Leuven, Vlaams-Brabant, Belgium
CHU de Liege ( Site 4400)
Liège, Wallonne, Region, Belgium
University Of Alberta Hospital ( Site 4702)
Edmonton, Alberta, Canada
St. Joseph's Health Care London ( Site 4701)
London, Ontario, Canada
Mount Sinai Hospital [Toronto, Canada] ( Site 4700)
Toronto, Ontario, Canada
Centro de especialidades médicas Vanguardia ( Site 4850)
Temuco, Araucania, Chile
BIOCINETIC Ltda ( Site 4854)
Santiago, Region M. de Santiago, Chile
Centro de Investigacion Clinica UC CICUC ( Site 4855)
Santiago, Region M. de Santiago, Chile
Centro Internacional de Estudios Clinicos CIEC ( Site 4851)
Santiago, Region M. de Santiago, Chile
Clinica Dermacross ( Site 4853)
Vitacura, Region M. de Santiago, Chile
ONCOCENTRO APYS ( Site 4852)
Viña del Mar, Valparaiso, Chile
Hopital Cochin ( Site 4203)
Paris, France
CHU de Bordeaux. Hopital Pellegrin ( Site 4202)
Bordeaux, Nord, France
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.